Standout Papers

<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors 2000 2026 2008 2017 1.7k
  1. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors (2003)
    Michael C. Heinrich, Christopher L. Corless et al. Science
  2. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor (2000)
    Michael C. Heinrich, Diana Griffith et al. Blood
  3. PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib (2005)
    Christopher L. Corless, Arin Schroeder et al. Journal of Clinical Oncology
  4. Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor (2008)
    Michael C. Heinrich, Robert G. Maki et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 16 from Science/Nature 113 standout
Sub-graph 1 of 15

Citing Papers

Challenges and Opportunities in Cancer Drug Resistance
2020 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
122 intermediate papers

Works of Diana Griffith being referenced

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
2008 Standout
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
2003 StandoutScience
and 9 more

Author Peers

Author Last Decade Papers Cites
Diana Griffith 1124 2829 845 2609 1374 22 5.0k
Laura McGreevey 926 3459 714 3252 1788 16 5.3k
Ajia Town 747 2821 1162 2891 1404 17 5.2k
Sandra Silberman 1122 3407 1012 3900 1752 38 6.7k
Y Moriyama 711 2642 435 2217 1419 24 4.0k
Koji Isozaki 584 4323 643 3403 2258 31 5.6k
Saša Dimitrijević 1428 4193 1469 4761 2099 48 8.3k
Masato Hanada 405 2692 384 2403 1580 50 3.9k
A. van Oosterom 586 2500 848 3665 1297 85 6.0k
Anette Duensing 517 3032 1897 2879 1669 90 6.6k
Zariana Nikolova 720 957 741 1341 528 52 3.0k

All Works

Loading papers...

Rankless by CCL
2026